{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Biotech Intuition","title":"Biotech Daily - 15th October 2026","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/a2bf4a7d\"></iframe>","width":"100%","height":180,"duration":419,"description":"This digest covers key developments from AstraZeneca, insitro, Takeda, Krystal Biotech, Labcorp Holdings and OMass Therapeutics, including a billion-dollar AI target-discovery collaboration, the first orexin agonist launch for narcolepsy type 1, positive early dermatology clinical data in Gorlin syndrome, a $722 million diagnostics asset acquisition, an FDA-accepted NDA resubmission and a $310 million Series C, alongside broader coverage across the sector. \nThis brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.","thumbnail_url":"https://img.transistorcdn.com/9CRjd85JHtM1TuR9eJILKciqKkE8Zi-g-0T-xOirVCU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wZGRl/OGVlNDg2NjQ1MmUx/OTMyMjcxZmY3Zjdk/N2JiYS5qcGVn.webp","thumbnail_width":300,"thumbnail_height":300}